Can Meloxicam Be Used for Coccygeal (Tailbone) Pain?
Yes, meloxicam can be used for coccygeal pain as a first-line NSAID option, given at 15 mg daily, based on its demonstrated efficacy for musculoskeletal pain and inflammatory conditions. While no guidelines specifically address coccydynia treatment, meloxicam falls within the broader NSAID class recommended for persistent musculoskeletal pain.
Evidence-Based Rationale
NSAID Use for Musculoskeletal Pain
The 2009 JAGS guidelines on persistent pain management in older persons establish that NSAIDs and COX-2 selective inhibitors may be considered for musculoskeletal pain, though with extreme caution and only when safer therapies have failed 1. Meloxicam, as a preferential COX-2 inhibitor, offers a favorable balance between efficacy and gastrointestinal safety compared to non-selective NSAIDs.
Specific Evidence for Meloxicam in Spinal Pain
Research demonstrates meloxicam's effectiveness for conditions similar to coccydynia:
- Periradicular injection of meloxicam (10 mg) provided long-lasting pain relief for chronic low back pain and sciatica, with 50% of patients requiring no further injections and 86% avoiding rescue analgesia 2
- Oral meloxicam 15 mg showed significant pain improvement in acute sciatica within 30 minutes, with good tolerability 3
- The 2025 CNO guidelines list meloxicam 15 mg/day as a first-line NSAID option for bone-related inflammatory pain 4
Dosing Recommendation
Start with meloxicam 15 mg once daily orally 4. This represents the maximum approved dose and is most likely to provide adequate analgesia for coccygeal pain. Evaluate response at 2-4 weeks 4.
Critical Safety Considerations
Absolute Contraindications
Do not use meloxicam if the patient has:
Relative Contraindications Requiring Caution
- Hypertension
- History of peptic ulcer disease or H. pylori infection
- Concomitant use of corticosteroids or SSRIs
- Concomitant aspirin use (increases GI bleeding risk >10-fold) 5
Gastrointestinal Protection
If the patient is taking aspirin or has GI risk factors, add a proton pump inhibitor 1. The 2009 JAGS guidelines provide strong recommendations that patients taking COX-2 selective inhibitors with aspirin should use gastroprotection 1.
Monitoring Requirements
Routinely assess for gastrointestinal and renal toxicity, hypertension, heart failure, and drug-drug interactions 1. This is particularly important given that meloxicam, despite being COX-2 preferential, still carries cardiovascular and renal risks similar to other NSAIDs.
Treatment Algorithm for Coccydynia
First-line: Meloxicam 15 mg daily orally for 2-4 weeks
- Add PPI if taking aspirin or has GI risk factors
- Monitor blood pressure, renal function, and GI symptoms
If insufficient response at 2-4 weeks: Consider:
- Local coccygeal steroid injection (demonstrated efficacy in adolescent coccydynia with 60% achieving no/minimal pain) 6
- Continue meloxicam if partial response
- Switch to alternative NSAID if no response
Adjunctive measures (based on coccydynia literature):
Important Caveats
No NSAID should be used long-term without ongoing risk-benefit assessment 1. The evidence for meloxicam in coccydynia specifically is extrapolated from its use in other spinal pain conditions and general musculoskeletal pain. The 2011 study on adolescent coccydynia showed that NSAIDs were effective as initial treatment in 12/53 patients, though many required escalation to steroid injections 6.
Meloxicam offers no unique advantage over other NSAIDs for coccydynia, but its once-daily dosing and preferential COX-2 selectivity may improve adherence and reduce GI side effects compared to non-selective NSAIDs. Recent data suggest meloxicam may result in higher opioid consumption compared to ketorolac in postoperative settings 8, though this may not be relevant to chronic coccydynia management.
The maximum duration of NSAID therapy should be as short as possible to minimize cardiovascular and renal risks, with transition to non-pharmacologic interventions or procedural options if pain persists beyond 4-6 weeks 1.